ABPI appoints Dr Jacintha Sivarajah as Head of Medical Affairs

To lead policy work on medical practice and clinical research

The Association of the British Pharmaceutical Industry (ABPI) has hired Dr Jacintha Sivarajah as Head of Medical Affairs.

Sivarajah will be responsible for leading the Association's policy work on medical practice and clinical research and for representing the industry with its key stakeholders in the healthcare services, professional societies and medical and clinical research organisations.

In her most recent role, Dr Sivarajah worked for GSK as Medical Affairs Manager of the haematology-oncology team and prior to this as a Senior Medical Advisor supporting the UK pharmaceutical company's haematology-oncology portfolio. Before joining GSK, Dr Sivarajah worked for Sanofi for three years supporting the company's cardiovascular, thrombosis and diabetes portfolios.

Dr Sivarajah qualified as a physician from King’s College London in 2002 and worked for a number of years within the NHS while also undertaking a training programme in internal medicine obtaining her MRCP (Member of the Royal College of Physicians) qualification in 2006.

You may also like

Drug Delivery

ABPI: “New antibiotics key against resistance infections”

In 2019, it was estimated that 1.2 million deaths globally, were due to antibiotic-resistant infections
Regulatory

ABPI: Tackling vaccine hesitancy should be a priority

The Association of the British Pharmaceutical Industry responds to the UK's commitment to improving declining vaccination rates
Regulatory

New medicine safety initiative goes live across the UK and Europe

The ABPI raises concerns about the safety of the UK's medicines in a ‘no deal’ Brexit
Research & Development

ABPI urges the UK to address the skills shortage in STEM

Highly skilled scientific roles could move elsewhere if the situation is not addressed as a matter of urgency
Regulatory

Waiting in the shadow of a no deal Brexit

Pharmaceutical companies still do not know how they will be impacted by Brexit after Prime Minister Theresa May decided to postpone a vote on her deal with the European Union (EU), writes Paul Brooks, Executive Director, RAPS
Regulatory

NHS, Pharma and Biotech industries call on Government to protect patients in future UK-EU relationship

A coalition from the UK’s health sector say Brexit negotiators have a responsibility to protect 500 million patients on both sides of the Channel. The group is calling on both sides to make patients and public health central to the Political Declaration for the future relationship between the UK and the EU
Research & Development

Scotland’s manufacturing exports worth £462 million

The Scottish pharmaceutical industry is ‘booming’ and is now the second biggest spender on R&D, a new report has revealed
Subscribe now